Screener
AbCellera Biologics Inc. ABCL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Three months ended June 30, 2025 | Three months ended June 30, 2026 | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|---|---|
| Total operating expenses | 66,669 | 66,827 | 133,566 | 132,662 |
| Loss from operations | (49,585) | (62,777) | (112,246) | (120,300) |
| Other (income) expense: | ||||
| Interest and other | (9,549) | 42 | (15,073) | (3,606) |
| Grants and incentives | (3,692) | (3,854) | (7,845) | (8,193) |
| Total other income | (13,241) | (3,812) | (22,918) | (11,799) |
| Loss before income tax | (36,344) | (58,965) | (89,328) | (108,501) |
| Income tax recovery | (1,617) | (3,538) | (8,980) | (9,909) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s interest expense?
- AbCellera Biologics Inc. (ABCL) reported interest expense of -$42K in Q2 2026.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about AbCellera Biologics Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude